ALK inhibitors have presented an opportunity for the individualized treatment of lung cancers and provided an alternative therapeutic approach for those patients intolerant to chemotherapy and radiation therapy (Hao et al. 2015; Kwak et al. 2010). This evidence concerns the gene ALK and lung cancer.